conference paper
The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.
July 1, 2021
Cancer Research
Type
conference paper
Web of Science ID
WOS:000680263502022
Author(s)
Codarri-Deak, Laura
Umana, Pablo
Klein, Christian
Date Issued
2021-07-01
Publisher
Publisher place
Philadelphia
Published in
Cancer Research
Volume
81
Issue
13
Subjects
Editorial or Peer reviewed
REVIEWED
Written at
EPFL
EPFL units
Available on Infoscience
September 11, 2021
Use this identifier to reference this record